Prevention of cis-platinum nephrotoxicity in a high-risk patient.
A 64-year-old woman, affected by stage IIIc epithelial ovarian cancer, experienced acute renal failure after the first cycle of chemotherapy with cyclophosphamide and cis-platinum, despite standard prophylactic measures of hydration-diuresis. In this paper we report data obtained during 5 additional cycles of chemotherapy. The schedule of treatment was modified by dividing standard dose of cis-platinum by three and administering this divided dose for 3 days. The following five cycles of treatment did not cause a clinically relevant impairment of glomerular function or evident tubular toxicity. A high-risk patient was treated safely combining hydration-diuresis measures with lengthening of cis-platinum administration over 3 days.
Donadio
C
C
Unità di Nefrologia Clinica Medica 2, Università di Pisa, Italy.
Lucchesi
A
A
Gadducci
A
A
D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004231:Diuresis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D003404:Creatinine; D002945:Cisplatin